A detailed history of Vident Advisory, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Vident Advisory, LLC holds 15,396 shares of EXAS stock, worth $720,686. This represents 0.02% of its overall portfolio holdings.

Number of Shares
15,396
Previous 28,177 45.36%
Holding current value
$720,686
Previous $2.08 Billion 48.99%
% of portfolio
0.02%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$56.27 - $73.77 $719,186 - $942,854
-12,781 Reduced 45.36%
15,396 $1.06 Billion
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $1,712 - $2,195
-29 Reduced 0.1%
28,177 $2.08 Billion
Q3 2023

Feb 21, 2024

BUY
$65.94 - $99.04 $1,912 - $2,872
29 Added 0.1%
28,206 $1.92 Billion
Q3 2023

Nov 14, 2023

BUY
$65.94 - $99.04 $1.86 Million - $2.79 Million
28,206 New
28,206 $1.92 Billion

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.28B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.